 Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 1 | 4 | | 1994 | 5 | 0 | 5 | | 1995 | 5 | 0 | 5 | | 1996 | 4 | 1 | 5 | | 1997 | 5 | 1 | 6 | | 1998 | 7 | 0 | 7 | | 1999 | 5 | 0 | 5 | | 2000 | 6 | 2 | 8 | | 2001 | 4 | 1 | 5 | | 2002 | 5 | 3 | 8 | | 2003 | 5 | 2 | 7 | | 2004 | 4 | 1 | 5 | | 2005 | 15 | 1 | 16 | | 2006 | 13 | 1 | 14 | | 2007 | 12 | 2 | 14 | | 2008 | 14 | 2 | 16 | | 2009 | 16 | 1 | 17 | | 2010 | 7 | 3 | 10 | | 2011 | 14 | 1 | 15 | | 2012 | 23 | 3 | 26 | | 2013 | 21 | 5 | 26 | | 2014 | 14 | 3 | 17 | | 2015 | 9 | 4 | 13 | | 2016 | 16 | 1 | 17 | | 2017 | 29 | 1 | 30 | | 2018 | 23 | 2 | 25 | | 2019 | 22 | 3 | 25 | | 2020 | 20 | 2 | 22 | | 2021 | 21 | 0 | 21 | | 2022 | 14 | 0 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Krishnan A, Bhasker AI, Singh MK, Rodriguez CI, Pérez EC, Altameemi S, Lares M, Khan H, Ndiaye M, Ahmad N, Schieke SM, Setaluri V. EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression. Mol Cancer Res. 2022 10 04; 20(10):1548-1560.
-
Alvarez-Breckenridge C, Markson SC, Stocking JH, Nayyar N, Lastrapes M, Strickland MR, Kim AE, de Sauvage M, Dahal A, Larson JM, Mora JL, Navia AW, Klein RH, Kuter BM, Gill CM, Bertalan M, Shaw B, Kaplan A, Subramanian M, Jain A, Kumar S, Danish H, White M, Shahid O, Pauken KE, Miller BC, Frederick DT, Hebert C, Shaw M, Martinez-Lage M, Frosch M, Wang N, Gerstner E, Nahed BV, Curry WT, Carter B, Cahill DP, Boland GM, Izar B, Davies MA, Sharpe AH, Suvà ML, Sullivan RJ, Brastianos PK, Carter SL. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunol Res. 2022 08 03; 10(8):996-1012.
-
Jarell A, Gastman BR, Dillon LD, Hsueh EC, Podlipnik S, Covington KR, Cook RW, Bailey CN, Quick AP, Martin BJ, Kurley SJ, Goldberg MS, Puig S. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol. 2022 Dec; 87(6):1312-1320.
-
Mullinax JE, Egger ME, McCarter M, Monk BJ, Toloza EM, Brousseau S, Jagasia M, Sarnaik A. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Cancer J. 2022 Jul-Aug 01; 28(4):285-293.
-
Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 2022 10 01; 32(5):324-333.
-
Moschos SJ, Sandhu S, Lewis KD, Sullivan RJ, Puzanov I, Johnson DB, Henary HA, Wong H, Upreti VV, Long GV, Flaherty KT. Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Invest New Drugs. 2022 10; 40(5):1051-1065.
-
Kurn HA, Abercrombie M, Tzellos T, Dellavalle RP. From the Cochrane library: Interventions for melanoma in situ, including lentigo maligna. J Am Acad Dermatol. 2022 09; 87(3):e115-e116.
-
Straker RJ, Krupp K, Sharon CE, Thaler AS, Kelly NJ, Chu EY, Elder DE, Xu X, Miura JT, Karakousis GC. Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. Ann Surg Oncol. 2022 Aug; 29(8):5207-5216.
-
Kavran AJ, Stuart SA, Hayashi KR, Basken JM, Brandhuber BJ, Ahn NG. Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge. Proc Natl Acad Sci U S A. 2022 03 22; 119(12):e2113535119.
-
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|